Zydus Lifesciences has received tentative approval from the US Food and Drug Administration to market Rifaximin Tablets in ...

Ahmedabad: Pharma major, Zydus Lifesciences Limited, has received tentative approval from the United States Food and Drug ...

Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration for Rifaximin ...

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets ...

As per the IQVIA data (March, 2025), the Rifaximin tablets had annual sales of $2,672.9 million in the US market.

Zydus Lifesciences receives FDA tentative approval for Rifaximin Tablets, 550 mg, for IBS-D treatment in adults.

Zydus Lifesciences Limited has received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg, ...

The deal values each share at $7.50, with the acquisition to be completed in cash within 60 days, subject to applicable ...

CVS Caremark will add Zydus' Zituvio™ and combination products ... (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.

Zydus Lifesciences receives USFDA approval for Rifaximin Tablets, a generic treatment for Irritable Bowel Syndrome with ...

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin Tablets, 550 mg (USRLD: Xifaxan Tablets, 550 mg).